

Revised June 2006

CURRICULUM VITAE



PERSONAL DATA

Name: Jonathan S. Steinberg, M.D.

Business Address: St. Luke's/Roosevelt
1111 Amsterdam Avenue
New York, NY 10025

Home Address: 268 Underhill Road
South Orange, NJ 07079

Social Security No. 092-44-3548

Birthdate: March 28, 1956

Birthplace: New York

Marital Status: Married, Two Children

Citizenship: USA

ACADEMIC TRAINING

9/72 – 6/76 AB - Queens College of the
City University of New York

9/76 – 6/80 MD - Mt. Sinai School of
Medicine, New York, NY

TRAINEESHIP

7/80 – 6/81	Medical Intern New York University - New York VA Medical Center New York, NY
7/81 – 6/83	Medical Resident New York University - New York VA Medical Center New York
7/83 – 6/84	Chief Medical Resident New York University New York VA Medical Center New York, NY

TRAINEESHIP (cont'd)

7/84 – 6/86	Clinical Cardiology Fellow George Washington University Medical Center, Washington, DC
7/86 – 6/88	Fellowship - Electrophysiology Columbia - Presbyterian Medical Center, New York, NY

LICENSURE

New York - 147162
New Jersey - MA57755

BOARD CERTIFICATION

1980	Diplomate, National Board of Medical Examiners
1983	Diplomate, American Board of Internal Medicine
1987	Diplomate, Subspecialty of Cardiovascular Diseases
1992	Diplomate, Clinical Electrophysiology

PROFESSIONAL ORGANIZATIONS AND SOCIETIES

Fellow - American College of Cardiology
Fellow - American College of Physicians
Fellow - Council on Clinical Cardiology, American Heart Association
Member - North American Society of Pacing & Electrophysiology
Member - International Society of Holter and Noninvasive Electrocardiology
Member - Cardiac Electrophysiology Society
Member - Board of Directors - American Heart Association, NYC Affiliate (2000-2004)
Chairman - Operation Heartbeat Outreach, American Heart Association, Heritage Affiliate (NYC, LI, CT, NJ) (2003-2004)

ACADEMIC APPOINTMENTS

1986 - 1987
Assistant in Clinical Medicine
Columbia University
College of Physicians & Surgeons
New York, NY

1987 - 1988
Assistant in Medicine
Columbia University
College of Physicians & Surgeons
New York, NY

ACADEMIC APPOINTMENTS (cont'd)

1988 - 1995
Assistant Professor of Clinical Medicine
Columbia University
College of Physicians & Surgeons
New York, NY

1996 - 2001
Associate Professor of Medicine
Columbia University
College of Physicians & Surgeons
New York, NY

2001-Present 4/05
Professor of Medicine
Columbia University
College of Physicians & Surgeons
New York, NY

HOSPITAL APPOINTMENTS

7/88 – 12/90
Assistant Attending Physician in
the Medicine Service
The Presbyterian Hospital
New York, NY

7/88 – 12/90
Associate Director
Cardiac Stress Laboratory
Columbia-Presbyterian Medical Center
New York, NY

7/88 – 12/90
Director, Signal-Averaged
Electrocardiography Laboratory
Columbia-Presbyterian Medical Center
New York, NY

7/88 – 12/90
Staff Electrophysiologist
Cardiac Electrophysiology &
Pacemaker Laboratory
Columbia-Presbyterian Medical Center
New York, NY

1/91 – 12/96
Associate Attending
The Medical Service
St. Luke's-Roosevelt Hospital Center
New York, NY

1/91 – Present 4/05
Director
Arrhythmia Service
St. Luke's - Roosevelt Hospital Center
New York, NY

HOSPITAL APPOINTMENTS (cont'd)

1/94 – 12/99
Director
Arrhythmia Service
St. Vincent's Medical Center of Richmond
Staten Island, New York

1/96 – Present 4/05
Director
Electrophysiology Laboratory
Valley Hospital
Ridgewood, New Jersey

1/96 – Present 4/05
Chief, Division of Cardiology
St. Luke's-Roosevelt Hospital Center

1/96 – 12/00
Co-Director, The Heart Center
St. Luke's-Roosevelt Hospital Center

1/96 – Present 4/05
Senior Attending
The Medical Service
St. Luke's-Roosevelt Hospital Center
New York, NY

1/00 – Present 4/05
Staff Electrophysiologist
Beth Israel Medical Center
New York, NY

HONORS and AWARDS

1976
Summa Cum Laude and Honors in Biology
Queens College

1976
Phi Beta Kappa
Queens College

1980
Mt. Sinai School of Medicine
Alumni Scholarship

FELLOWSHIP AND GRANT SUPPORT

1987 - 1988
John B. Sable Memorial Heart
Fund Fellowship

1988 American College of Cardiology/
Bristol Laboratories Travel Award

1988 - 1991 Investigatorship
American Heart Association/
New York City Affiliate

1989 - 1990 Bristol-Myers Scientific Grant

FELLOWSHIP AND GRANT SUPPORT (cont'd)

1989 – 1990 DuPont Pharmaceuticals Scientific Grant

1992 - 1993 Dupont Pharmaceuticals Scientific Grant

1993 - 1994 Hewlett-Packard Scientific Grant

1996 - 1997 Principal Investigator, “Natural History of
Patients with Unexplained Syncope and
Inducible VT: An AVID Substudy”; supported
by NHLBI

1996-1997 Marquette Electronics Scientific Grant

DEPARTMENTAL AND UNIVERSITY COMMITTEES

1991 - Present Executive Committee
Division of Cardiology
St. Luke's/Roosevelt Hospital Center

1991 - Present Housestaff Selection Committee
Department of Medicine
St. Luke's/Roosevelt Hospital Center

1994 - 1995 Chairman, Hospital Task Force on Admitting,
St. Luke's-Roosevelt Hospital Center

1995 - Present Chairman, Technology Assessment Committee,
St. Luke's-Roosevelt Hospital Center

1995 - 1996 Strategic Repositioning Working Group,
St. Luke's-Roosevelt Hospital Center

1995 - 1996 Cardiology Project Committee
St. Luke's-Roosevelt Hospital Center

1995 - 1999 Operations and Executive Committees,
Heart Center of St. Luke's-Roosevelt
Hospital Center

1997 - 1998 Member, Search Committee
for the Director, Emergency Department

1997 - 1998	Member, Search Committee for the Chairman, Dept. of Surgery
1998 - Present	Member, Faculty Practice Oversight Committee, Dept. of Medicine

DEPARTMENTAL AND UNIVERSITY COMMITTEES (cont'd)

1999 - Present	Member, Continuum Heart Institute Executive and Operating Committees
2001	Member, Search Committee for the Executive Director, Continuum Heart Institute
2001	Member, Patient Care Committee, Columbia University College of Physicians & Surgeons
2001-present	Member, Executive Committee, Department of Medicine, Columbia-Presbyterian Medical Center

TEACHING EXPERIENCE AND RESPONSIBILITIES

Director, Cardiovascular Electrophysiology Fellowship,
St. Luke's-Roosevelt Hospital Center, 1991-present

Trainees:

- Dwayne Siu, DO 1991-2
- Steven Zelenkofske, DO 1992-3
- Sanjay Prasher, MD 1993-4
- Leigh Ann Hutchinson, MD 1994-6
- Luis Carrillo, MD 1995-7
- Margot Vloka, MD 1996-8
- Dhiraj Narula, MD 1997-9
- Anton Sutandar, MD 1998-2000
- Rajaa Kaddaha, MD 1999-2001
- Kataneh Maleki, MD 2000-2002
- David Hart, MD 2001-2003
- Aysha Arshad, MD 2002-2004
- Shuba Gowda, MD 2004-2005
- Arti Shah, MD 2005 - present

Clinical Cardiology Fellowship, St. Luke's-Roosevelt Hospital Center
Annual Lecture/Clinical Teaching –
ECG & Electrophysiology – 1991-Present
Interim Director, Training Program – 1997-1999

American College of Physicians Internal Medicine Board Review Course 1995-1997

Recipient, Guidant Foundation Electrophysiology Fellowship Grant – 1998-99, 1999-2000, 2000-2001, 2001-2002

Recipient, Medtronic Foundation Electrophysiology Fellowship Grant – 2004-2005, 2005-2006

OTHER PROFESSIONAL ACTIVITIES

Multicenter Studies and Clinical Trials-Executive Positions

Member, Steering Committee, Late Assessment of Thrombolytic Efficacy (LATE) Ancillary Studies, supported by Genentech, Inc.

Director, Signal-Averaged ECG Core Laboratory of the LATE Ancillary Studies, supported by Genentech, Inc.

Member, Steering Committee, Antiarrhythmic Drugs Versus Implantable Defibrillator (AVID), supported by the NHLBI.

Co-chairman, Quality of Life Subcommittee in AVID, supported by the NHLBI.

Member, Steering Committee, Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM), supported by the NHLBI.

Chairman, Events Committee, Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM), supported by the NHLBI.

Member, Events Committee, COMPANION Trial of Biventricular Pacing, sponsored by Guidant, Inc.

Member, Executive Committee, Cardiomyopathy and Syncope Study (CASIS), sponsored by Guidant, Inc.

Member, Planning Committee, Hybrid Therapy for Atrial Fibrillation, sponsored by St. Jude Medical, Inc.

Study Chairman, Hybrid Therapy of Atrial Fibrillation Trial (HYTAFT), sponsored by Medtronic, Inc.

Co-Study Chairman, Randomized Comparison of Epicardial Versus Endovascular Leads for Resynchronization Trial (REVERT), sponsored by Medtronic, Inc.

Chairman, Data and Safety Monitoring Board, BLOCK-HF Trial, sponsored by Medtronic, Inc.

Multicenter Studies and Clinical Trials-Investigator Positions

Investigator, Cardiac Arrhythmia Suppression Trial (CAST), supported by the NHLBI.

Investigator, Electrophysiology Study Versus Electrocardiographic Monitoring Study (ESVEM), supported by the NHLBI.

Principal Investigator, Multicenters Automatic Defibrillator Implantation (MADIT) Trial Supported by Cardiac Pacemakers, Inc.

Principal Investigator, Flecainide for Supraventricular Tachycardia, supported by Riker-3M, Inc.

Principal Investigator, Intravenous Amiodarone for Recurrent Refractory Ventricular Tachycardia, supported by Wyeth-Ayerst Research.

Principal Investigator, DL Sotalol for Rate Control of Chronic Atrial Fibrillation, supported by Bristol-Myers Squibb, Inc.

Principal Investigator, DL Sotalol for Maintenance of Sinus Rhythm After Conversion of Atrial Fibrillation, supported by Bristol-Myers Squibb, Inc.

Principal Investigator, Intravenous Amiodarone for Refractory Cardiac Arrest, supported by Wyeth-Ayerst Research.

Principal Investigator, Comparison of Intravenous Amiodarone and Bretylium for Refractory Ventricular Tachycardia, supported by Wyeth-Ayerst Research.

Principal Investigator, Evaluation of Bidisomide for Termination of Supraventricular Tachycardia, supported by Searle, Inc.

Principal Investigator, Evaluation of Bidisomide for Termination of Ventricular Tachycardia, supported by Searle, Inc.

Principal Investigator, Comparison of Sematilide and Quinidine for suppression of Inducible Ventricular Tachycardia, supported by Berlix, Inc.

Principal Investigator, Phase II Multicenter Pilot Study to Examine Activity of Different Doses of Bidisomide in Subjects with Inducible Ventricular Tachycardia, supported by Searle, Inc.

Principal Investigator, Phase II Investigation of CPI Ventak Prx System in Combination with the Endotak Lead System, Supported by CPI, Inc.

Principal Investigator, Clinical Investigation of the Cadence Tiered Therapy Defibrillator System, supported by Ventritex, Inc.

Principal Investigator Randomized Clinical Trial Comparing Norpace-CR and Quinidine Gluconate in the Prevention of Atrial Fibrillation, supported by Searle, Inc.

Principal Investigator, Single-Blind Comparison of Norpace Versus Kerlone or Placebo in the Treatment of Neurally-Mediated Syncope, supported by Searle, Inc.

Principal Investigator, Multicenter Automatic Defibrillator Implantation Trial, supported by CPI, Inc.

Principal Investigator, D-Sotalol Mortality Trial After Myocardial Infarction, supported by Bristol-Myers Squibb.

Principal Investigator, Double Blind Comparison of Bidisomide and Placebo for Prevention of Atrial Fibrillation, supported by Searle, Inc.

Principal Investigator, Randomized Double-blind study of Dofetilide and placebo in patients with a ICD, supported by Pfizer, Inc.

Investigator, Randomized Comparison of Digoxin and Diltiazem for Rate Control of Atrial Fibrillation, supported by Marion Merrill Dow, Inc.

Principal Investigator, Investigation of the Cadence TVL ICD System, supported by Ventritex, Inc.

Principal Investigator, Clinical Investigation of the Hot Can Defibrillator PRX III Hot Can Defibrillator, supported by CPI, Inc.

Principal Investigator, Amio-Aqueous in the Medical Management of Incessant Life Threatening Ventricular Arrhythmia, supported by Academic Pharmaceuticals, Inc.

Principal Investigator, Azimilide for the Prevention of Atrial Fibrillation and SVT, supported by Proctor & Gamble, Inc.

Principal Investigator, Azimilide in Patients with an ICD for Treatment of Ventricular Arrhythmia.

Principal Investigator, Sudden Cardiac Death Heart Failure Trial, supported by NHLBI.

Principal Investigator, MADIT II, supported by CPI, Inc.

Principal Investigator, Evaluation of the Constellation basket catheter, supported by EPT, Inc.

Principal Investigator, Tedisamil for the treatment of atrial fibrillation, supported by Solvay, Inc.

Principal Investigator, IV Tedisamil for Termination of AF, supported by Solvay, Inc.

Principal Investigator, Clinical Investigation of the Gem ICD supported by Medtronic, Inc.

Principal Investigator, Evaluation of the Stinger Catheter Ablation System, supported by Bard, Inc.

Co-Principal Investigator, ACUTE Trial, supported by NHLBI

Principal Investigator, Stockert Ablation System, supported by Cordis-Webster, Inc.

Principal Investigator, MIRACLE Trial of Biventricular Pacing for CHF, supported by Medtronic, Inc.

Principal Investigator, Fatty Acid Antiarrhythmic Trial, supported by NHLBI.

Co-Principal Investigator, COMPANION Study of Biventricular Pacing, supported by Guidant, Inc.

Principal Investigator, Triggers of Ventricular Arrhythmias, supported by NIH.

Principal Investigator, Dose-Ranging and Tolerability Study of Dronedarone in Patients With ICDs, supported by Sanofi-Synthelabo Research.

Principal Investigator, Left Ventricular-Based Cardiac Stimulation Post AV Node Ablation Evaluation (PAVE), supported by St. Jude Medical, Inc.

Principal Investigator, Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial, supported by St. Jude Medical, Inc.

Principal Investigator, Evaluation of ThermoCool Irrigation Tip Catheter for Ablation of Atrial Fibrillation, sponsored by Biosense Cordis-Webster, Inc.

Principal Investigator, Evaluations of Cryocath Technology for Catheter Ablation, sponsored by Cryocath, Inc.

Principal Investigator, SPORTIF Trial, sponsored by Astra-Zeneca, Inc.

Principal Investigator, Protocol SBZ07266/082 for The Study of Symptomatic Persistent Atrial Fibrillation, sponsored by GlaxoSmithKline Inc.

Principal Investigator, Hybrid Therapy for Atrial Fibrillation Trial (HYTAFT) supported by Medtronic, Inc.

Principal Investigator, Shock Inhibition Evaluation with Azimilide, sponsored by Proctor & Gamble, Inc.

Principal Investigator, Atrial Fibrillation and Congestive Heart Failure (AF-CHF) Trial, supported by Canadian Institutes of Health Research.

Principal Investigator, Arrhythmogenic Right Ventricular Dysplasia Registry, supported by NHLBI.

Principal Investigator, DAVID II Trial, supported by St. Jude Medical, Inc.

Principal Investigator, Contak Renewal Heart Failure Heart Rate Variability Registry (HF-HRV), supported by Guidant Corp.

Principal Investigator, Wireless Automatic Mobile Monitoring for ICD's (WAMMI), supported by Biotronik, Inc.

Principal Investigator, Registry of Cardiac Resynchronization Therapy (Restore- US), supported by Medtronic, Inc.

Principal Investigator, Shock Inhibition Evaluation with Azimilide Open Label (SHIELD-OL), supported by Proctor and Gamble Pharmaceuticals.

Principal Investigator; Cardiac Resynchronization Therapy Registry Evaluating Patient Response with RENEWAL Family Devices (CRT Renewal) Registry, Supported by Guidant.

Principal Investigator, Evaluation of Riata Integrated and Dedicated Bipolar Leads with CRT Devices, supported by St. Jude Medical.

Principal Investigator, Evaluation of the Safety and Efficacy of the OPTIMIZER System with Active Fixation Leads in Subjects with Heart Failure Resulting from Systolic Dysfunction (FIX-HF-5), supported by Impulse Dynamics.

Principal Investigator, AF Suppression Pacing to Prevent First Episode of Atrial Fibrillation in High Risk ICD Patients (ASPEN-ICD), supported by St. Jude Medical.

Principal Investigator, Clinical Study to Evaluate the Safety and Efficacy of the CryoCor Cardiac Cryoablation System for the Treatment of Paroxysmal Atrial Fibrillation (ICE-PAF), supported by CryoCor, Inc.

Co-Principal Investigator, Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT), supported by Guidant.

Investigator, Home Automatic Defibrillator Trial (HAT), supported by NHLBI

Co-Principal Investigator, Randomized Study of Endovascular Versus Epicardial Lead Placement for Resynchronization Therapy (REVERT) Study, supported by Medtronic

Investigator, AV Node Ablation with CLS and CRT Pacing Therapies for the treatment of AF (AVAIL), sponsored by Biotronik.

Investigator, Double-Blind Placebo controlled Dose Ranging Study of the Efficacy and Safety of SSR149744C 100 or 300mg for the Prevention of Ventricular Arrhythmia Triggered ICD Interventions (ICARIOS), sponsored by Sanofi-Adventis

Investigator, A Placebo Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg bid for the Prevention of Cardiovascular Hospitalization or Death From any Cause in Patients with Atrial Fibrillation/ Atrial Flutter, sponsored by Sanofi-Adventis

Principal Investigator, The Use of the LifeWatch Lifestar AF Express to Detect Asymptomatic Atrial Fibrillation Following Pulmonary Vein Ablation., sponsored by LifeWatch Inc.

Investigator, Response of Cardiac Resynchronization Therapy Optimization with V-V Timing in Heart Failure Patients (Response HF), sponsored by St.Jude Medical.

Principal Investigator, Navistar Thermocool Catheter for the Radiofrequency ablation of symptomatic Paroxysmal Atrial Fibrillation IDE# G030236, sponsored by Biosense Webster.

Editorial (Reviewer)

American Journal of Cardiology
Journal of Cardiovascular Pharmacology
Stroke
Circulation
PACE
Journal of the American College of Cardiology
Journal of Electrocardiology
American Heart Journal
Journal of Cardiovascular Electrophysiology
Coronary Artery Disease
Obesity Research
Journal of Interventional Cardiac Electrophysiology
Journal of Thoracic and Cardiovascular Surgery
Heart
Annals of Internal Medicine
Journal of the American Medical Association
Annals of Noninvasive Electrocardiology
Heart Rhythm
The International Journal of Cardiology

Abstract Grader, NASPE
Abstract Grader, American Heart Association
Abstract Grader, American College of Cardiology

Editorial Board

Annals of Noninvasive Electrocardiology (Section Editor: Defibrillation/Resynchronization)
Folia Cardiologica

National/International Committee Positions

Co-chairman and Principal Author, Technical Standards Committee for Signal-Averaged Electrocardiogram, Association for the Advancement of Medical Instrumentation

Governor for U.S.A., International Society of Holter & Noninvasive Electrocardiology, 1999-present
Treasurer, International Society of Holter & Noninvasive Electrocardiology, 2005-present

FDA Submission Panel Member, Guidant Inc. for COMPANION, July 2004

Member, American Society of Echocardiography Dyssynchrony Writing Group

Special Coursework

Physician Leadership of Academic Health Centers, Harvard School of Public Health,
October 1997

Grant Review

National Heart, Lung and Blood Institute, Special Emphasis Panel, 2000-present

Scottish Executive Health Department - 2006

PUBLICATIONS

ORIGINAL, PEER REVIEWED ARTICLES

1. * **Steinberg JS**, Wasserman AG. Doxorubicin cardiotoxicity: the use of radionuclide ventriculography for evaluation and prevention. *Clin Ther* 1985; 7:660-7.
2. * **Steinberg JS**, Katz RJ, Somberg JC, Keefe D, Laddu AR, Burge J. Safety and efficacy of flestolol, a new ultrashort-acting beta adrenergic blocking agent. *Am J Cardiol* 1986; 58:1005-8.
3. * **Steinberg JS**, Katz RJ, Bren JB, Buff L, Varghese PJ. Efficacy of oral diltiazem to control rest and exercise ventricular response in atrial fibrillation. *J Am Coll Cardiol* 1987; 9:405-411.
4. * **Steinberg JS**, Cohen AJ, Wasserman AG, Cohen P, Ross AM. Acute arrhythmogenicity or doxorubicin administration. *Cancer* 1987; 60:1213-1218.
5. Antunes ML, Spotnitz HM, Livelli FD, Jr., **Steinberg JS**, Bigger JT, Jr. Effect of electrophysiologic testing on ejection fraction during cardioverter/defibrillator implants. *Ann Thorac Surg* 1988; 45:315-418.
6. * **Steinberg JS** and Bigger JT, Jr. Importance of the endpoint of noise reduction in analysis of the signal averaged electrocardiogram. *Am J Cardiol* 1989; 63:556-560.
7. Kral MA, Spotnitz HM, Hordof A, Bigger JT, Jr., **Steinberg JS**, Livelli FD, Jr. Automatic implantable cardioverter defibrillator for malignant ventricular arrhythmias associated with congenital heart disease. *Am J Cardiol* 1989;63:118-119.
8. The ESVEM Investigators. The ESVEM trial: electrophysiologic study versus electrocardiographic monitoring for selection of antiarrhythmic therapy of ventricular tachyarrhythmias. *Circulation* 1989; 70:1354-1360.
9. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Increased mortality due to encainide or flecainide in a randomized trial of arrhythmia suppression after myocardial infarction. *N Eng J Med* 1989;321:406-412.
10. * **Steinberg JS**, Berbari EJ, Lander P. Signal averaged electrocardiography directly from Holter monitor tapes. *J Electrocardiol* 1990;22 Supplement:25-32.
11. * **Steinberg JS** and Sugalski JS. Cardiac rhythm precipitating automatic implantable defibrillator discharge in outpatients as detected from transtelephonic electrocardiographic recordings. *Am J Cardiol* 1991;67:95-97.
12. * Wechsler ME, **Steinberg JS**, Giardina EGV. Time course of moricizine's effect on the signal-averaged and 12-lead electrocardiograms: insights into mechanism of action. *J Am Coll Cardiol* 1991; 17:1626-1633.
13. Freedman RA and **Steinberg JS** . Selective prolongation of late potentials by sodium channel blocking antiarrhythmic drugs: relation to slowing of ventricular tachycardia. *J Am Coll Cardiol* 1991; 17:1017-1025.

PUBLICATIONS (cont'd)

14. Wyse GD, Hallstrom A, McBride R, Cohen J., **Steinberg JS** and the CAST investigators. Events in the Cardiac Arrhythmia Suppression Trial (CAST). Part III: mortality in patients surviving open-label titration but not randomized to double-blind therapy. *J Am Coll Cardiol* 1991; 18:20-8.
15. * **Steinberg JS**, Sahar D, Rosenbaum M, Cook J, Bigger JT, Jr. Proarrhythmic effects of procainamide and tocainide in a canine infarction model. *J CV Pharm* 1992; 19:52-59.
16. * **Steinberg JS**, Regan A, Sciacca RR, Bigger JT, Jr, Fleiss JL. Predicting arrhythmic events after myocardial infarction using the signal-averaged ECG. *Am J Cardiol* 1992; 69:13-21.
17. Spotnitz HM, Oh G, Bigger Jr., JT, **Steinberg JS**, Livelli Jr., F. Methods of ICD- pacemaker insertion to avoid interactions. *Ann Thor Surg* 1992; 53:253-257.
18. Freedman RA, Karagonnis L, **Steinberg JS**. Effects of sotalol on the signal-averaged ECG in patients with sustained ventricular tachycardia: relation to suppression of inducibility and changes in tachycardia cycle length. *J Am Coll Cardiol* 1992; 20:1213-1219.
19. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. *N Engl J Med* 1992; 327:227-233.
- 20.* Guidera S and **Steinberg JS** . The signal-averaged P-wave duration: a rapid and noninvasive marker of risk of atrial fibrillation. *J Am Coll Cardiol* 1993; 21:1645-51.
21. The ESVEM Investigators. Determinants of predicted efficacy of antiarrhythmic drugs in the Electrophysiologic Study Versus Electrocardiographic Monitoring Trial. *Circulation* 1993; 87:323-329.
22. * **Steinberg JS**, Zelenkofske S, Wong S.C, Gelernt M, Sciacca R, Menchavez E. The value of the p-wave signal-averaged electrocardiogram for predicting atrial fibrillation after cardiac surgery. *Circulation* 1993;88:2618-2622.
23. Mason JW for the ESVEM investigators. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. *N Eng J Med* 1993;329:445-451.
24. Mason JW for the ESVEM investigators. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. *N Eng J Med* 1993;329:452-458.
25. * **Steinberg JS**, Prystowsky E, Freedman RA, Moreno F, Katz R, Kron J, Regan A, Sciacca RR. Use of the signal-averaged electrocardiogram for predicting inducible ventricular tachycardia in patients with unexplained syncope: relationship to clinical variables in a multivariate analysis. *J Am Coll Cardiol* 1994;23:99-106.
26. * **Steinberg JS**, and Guidera SA. Signal-averaged P-wave duration and atrial fibrillation [letter]. *J Am Coll Cardiol* 1994;23:550.

PUBLICATIONS (cont'd)

27. * **Steinberg JS**, Hochman JS, Morgan CD, Dorian P, Naylor CD, Theroux P, Topol EJ, Armstrong PW and the LATE Ancillary Study Investigators. The effects of thrombolytic therapy administered 6-24 hours after myocardial infarction on the signal-averaged electrocardiogram: results of a multicenter randomized trial. *Circulation* 1994;90:746-752.
28. * **Steinberg JS**, Prasher S, Zelenkofske S, Ehlert FA. Radiofrequency catheter ablation of atrial flutter: success rate and predictors of outcome. *Am Heart J* 1995;130:85-92.
29. El-Gamal A, Gallagher D, Allison DB, **Steinberg JS**, Blank R, Heymsfeld SB. Effects of obesity on QT, RR and QTC intervals. *Am J Cardiol* 1995; 75:956-959.
30. Damm CJ, Bigger JT, Jr., Ursell PC, **Steinberg JS**, Smith R, Lennon PF, Cook JR. Computer-assisted mapping of infarcted and viable regions of gross cardiac sections following experimental myocardial infarction. *Comp Biomed Res* 1995;28:1-18.
31. Greenberg HM, Hochman JS, **Steinberg JS**, Echt DS, Peters RW, Dwyer ED. Interaction of ischemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I. *Br Heart J* 1995;74:631-635.
32. AVID Investigators. Antiarrhythmics versus implantable defibrillators (AVID)--rationale, design and methods. *Am J Cardiol* 1995;75:470-475.
33. * Hutchinson LA and **Steinberg JS**. A prospective study of atrial fibrillation after cardiac surgery: multivariate analysis using P-wave signal-averaged ECG and clinical variables. *ANE* 1996;1:133-140.
34. Kowey PR, Levine, JH, Herre JM, Pacifico A, Lindsay BD, Plumb VJ, Janosik DL, Kopelman HA, Scheinman MM for the IV amiodarone investigators. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically, destabilizing ventricular tachycardia or fibrillation. *Circulation* 1995;92:3255-3263.
35. Scheinman MM, Levine JH, Cannom DS, Friehling T, Kopelman HA, Chilson DA, Platia EV, Wilber DJ, Kowey PR for the IV amiodarone investigation. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. *Circulation* 1995;92:3264-3272.
36. * Ehlert FA, Zaman N and **Steinberg JS**. Immediate and short-term reproducibility of the P wave signal-averaged electrocardiogram. *PACE* 1997;20:1636-1645.
37. Lander P, Gomis P, Goyal R, Berbari E, Caminal P, Lazzara R, **Steinberg JS**. Analysis of abnormal intra-QRS potentials: improved predictive value for arrhythmic events using the signal-averaged electrocardiogram. *Circulation* 1997;95:1386-1393.
38. King ML, Lichtman SW, Seliger G, Ehlert F, **Steinberg JS**. Heart rate variability in chronic traumatic brain injury. *Brain Injury* 1997;11:445-453.

PUBLICATIONS (cont'd)

39. * Bloomfield D, Snyder JE, **Steinberg JS**. A critical appraisal of quantitative spectro-temporal analysis of signal-averaged ECG: predicting arrhythmic events after myocardial infarction. *PACE* 1996;19:768-777.
40. Porterfield JG, Morterfield, LM, Levine JH, Luceri RM, Hsia HH and the Cadence-Endotak C60 Series IDE Investigators. Compatibility of a nonthoracotomy lead system with a biphasic implantable cardioverter-defibrillator. *Am J Cardiol* 1996;77:586-590.
41. * Ehlert FA, Korenstein D, **Steinberg JS**. Evaluation of p-wave signal-averaged electrocardiographic filtering and analysis methods. *Am Heart J* 1997;134:985-993.
42. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Bertram P, Pratt CM, Schwartz PJ, Veltri EP for SWORD Investigators. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. *Lancet* 1996;348:7-12.
43. * Heller SS, Ormont MA, Lidagoster LC, Sciacca RR, **Steinberg JS**. Psychosocial outcome after ICD implantation: a current perspective *PACE* 1998;21:1207-1215.
44. Moss AJ, Hall WJ, Cannon DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M for the MADIT Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. *N Engl J Med* 1996;335:1933-1940.
45. * Pinsky DJ, Sciacca RR, **Steinberg JS**. QT dispersion as a marker of risk in patients awaiting heart transplantation. *J Am Coll Cardiol* 1997;29:1576-1584.
46. * Perera R, **Steinberg JS**, Ehlert FA, Mogtader A, Hillel Z. Left atrial function is unchanged by implantable defibrillator shocks on hearts in sinus rhythm. *Am J Cardiol* 1998;81:787-789
47. * Bloomfield D, **Steinberg JS**, Lander P, Freedman R. Slowed conduction with antiarrhythmic drugs reduces high frequency energy of the signal-averaged electrocardiogram. *ANE* 1998;3:220-227.
48. AVID Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. *N Engl J Med* 1997;337:1576-1583.
49. * Tamis JE and **Steinberg JS**. Value of the signal-averaged P wave analysis in predicting atrial fibrillation after cardiac surgery. *J Electrocardiol* 1998;30 Supplement:36-43.
50. The Atrial Fibrillation Investigation with Bidisomide (AFIB) Investigators. Treatment of atrial fibrillation and paroxysmal supraventricular tachycardia with bidisomide. *Circulation* 1997;96:2625-2632.
51. * Dorbala S, Cohen AJ, Hutchinson LA, Hutchinson, LA, Tan EM, **Steinberg JS**. Does radiofrequency ablation induce a prothrombotic state? Analysis of coagulation system activation and comparison to electrophysiologic study. *J Cardiovasc Electrophysiol* 1998;9:1152-1160.

PUBLICATIONS (cont'd)

- 52.* Chandrasekaran S and **Steinberg JS**. Efficacy of bretylium tosylate for ventricular tachycardia. *Am J Cardiol* 1999;83:115-117.
53. Brooks MM, Jenkins LS, Schron EB, **Steinberg JS**, Cross JA, Paeth DS. Quality of life at baseline: Is assessment after randomization valid? *Med Care* 1998;36:1515-1519.
54. Chan E, **Steinberg JS**, Santoni-Rugiu F, Gomes JA. P wave signal-averaged electrocardiography techniques. *ANE* 1998;3:147-152.
- 55.* Cossu S and **Steinberg JS**. Supraventricular tachyarrhythmias involving the sinus node: clinical and electrophysiologic characteristics. *Prog CV Dis* 1998;41:51-63.
56. Mushlin AI, Hall J, Zwanziger J, Gajary E, Andrews M, Marron R, Zou K, Moss AJ; for the MADIT Investigators. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. *Circulation* 1998;97:2129-2135.
- 57.* **Steinberg JS**, Gaur A, Sciacca RR and Tan E. New onset sustained ventricular tachycardia after cardiac surgery. *Circulation* 1999;99:903-908.
- 58.* Luchsinger JA and **Steinberg JS**. Resolution of cardiomyopathy after ablation of atrial flutter. *J Am Coll Cardiol* 1998;32:205-210.
- 59.* Bloomfield DM, Lander P and **Steinberg JS**. Changes in high frequency QRS energy in the signal-averaged electrocardiogram after acute experimental infarction. *ANE* 1999;4:72-82.
60. Chandrasekaran S, **Steinberg JS**, Slater JN, Palazzo AM, Morgan CD and Hochman JS. Relation between infarct artery patency at late angiography after acute myocardial infarction and signal-averaged electrocardiography. *Am J Cardiol* 1999;84:734-36.
- 61.* Menon V, **Steinberg JS**, Akiyama T, Beckman K, Carillo L and Kutalek S. Implantable cardioverter defibrillator discharge rates in patients with unexplained syncope, structural heart disease and inducible ventricular tachycardia at electrophysiologic study. *Clin Cardiol* 2000;23:195-200.
62. Amar D, Roistacher N, Zhang H, Baum MS, Ginsburg I, **Steinberg J**. Signal-averaged P-wave duration does not predict atrial fibrillation after thoracic surgery. *Anesthesiology* 1999;91:16-23.
- 63.* Babaev AA, Vloka ME, Sadurski R, **Steinberg JS**. Influence of age on atrial activation as measured by the P wave signal-averaged ECG. *Am J Cardiol* 2000;86:692-695.
- 64.* Tamis J and **Steinberg JS**. Atrial fibrillation independently prolongs hospital stay after coronary artery bypass surgery. *Clin Cardiol* 2000;23:155-159.
- 65.* Tamis-Holland JE, Homel P, Durani M, Iqbal M, Sutandar A, Mindich, BP, **Steinberg JS**. Atrial fibrillation after minimally invasive direct coronary artery bypass surgery. *J Am Coll Cardiol* 2000;36:1884-1888.

PUBLICATIONS (cont'd)

- 66.* Sadanandran S and **Steinberg JS**. Signal-averaged p wave: technique and clinical applications. *ANE* 1999;4(4):401-407.
- 67.* Sinakowicz RM, Narula D, Suster B, **Steinberg JS**. Diagnosis of amiodarone pulmonary toxicity with high resolution CT scan. *J Cardiovasc Electrophysiol* 2001; 12:431-436.
- 68.* **Steinberg JS**, Martins J, Sadanandan S, Goldner B, Menchavez E, Domanski M, Russo A, Tullo N, Hallstrom A, and the AVID Investigators. Antiarrhythmic drug use in the implantable defibrillator arm of the antiarrhythmics versus implantable defibrillators (AVID) study. *Am Heart J* 2001;142: 52-59
- 69.* **Steinberg JS**, Beckman K, Greene HL, Marinchak R, Klein RC, Greer SG, Ehlert F, Foster P, Menchavez E, Raitt M, Wathen MS, Morris M, Hallstrom A. Follow-up of patients with unexplained syncope and inducible ventricular tachyarrhythmias: analysis of the AVID registry and an AVID substudy. *J Cardiovasc Electrophysiol* 2001;12 996-1001
70. Hallstrom AP, Anderson JL, Cobb LA, Friedman PL, Herre JM, Klein RC, McAnulty J and **Steinberg JS** for the AVID Investigators. Advantages and disadvantages of trial designs: a review of analysis methods for ICD studies. *PACE* 2000;23:1029-1038.
71. The AVID Investigators. Causes of death in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. *J Am Coll Cardiol* 1999;34:1552-9.
72. The Planning and Steering Committees of the AFFIRM Study for the NHLBI AFFIRM Investigators. Atrial fibrillation follow-up investigation of rhythm management-the AFFIRM study design. *Am J Cardiol* 1997;79:1198-1202.
- 73.* Balcetyte-Harris N, Tamis-Holland JE and **Steinberg JS**. Randomized study of early intravenous versus oral beta-blockers in preventing atrial fibrillation in high risk patients undergoing coronary bypass surgery. *ANE* 2002;7:86-91
74. Raitt M, Renfroe EG, Epstein AE, McAnulty JH, Mounsey P, **Steinberg JS**, Lancaster SE, Jadonath RL, Hallstrom AP, for the AVID Investigators "Stable" ventricular tachycardia is not a benign rhythm: insights from the Antiarrhythmics Versus Implantable Defibrillators (AVID) registry. *Circulation* 2001; 103:224-252.
- 75.* Ehlert F, Cannom D, Renfroe EG, Greene HL, Ledingham R, Mitchell LB, Anderson JL, Halperin, BD, Herre JM, Luceri RM, Marinchak RA, **Steinberg JS**, and AVID Investigators. Comparison of dilated cardiomyopathy and coronary artery disease in patients with life-threatening ventricular arrhythmias: differences in presentation and outcome in the AVID registry. *Am Heart J* 2001; 142: 816-822.
- 76.* Li V, Dorbala S, Narula D, DePuey G, **Steinberg JS**. QT dispersion and viable myocardium in patients with prior myocardial infarction and severe left ventricular dysfunction. *ANE* 2002; 7: 53-59.

PUBLICATIONS (cont'd)

77. Moss AJ, Wojciech Z, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown M, Andrews ML and The MADIT II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. *N Engl J Med* 2002; 346: 877-890.
78. Schron EB, Exner DV, Yao Q, Jenkins LS, **Steinberg JS**, Cook JR, Kutalek SP, Friedman PL, Bubien RS, Page RL, Powell J, and the AVID Investigators. Quality of life in the Antiarrhythmics Versus Implantable Defibrillator Trial. *Circulation* 2002;105:589-594.
79. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Messenger J, for the MIRACLE Study Group. Cardiac resynchronization in chronic heart failure. *N Engl J Med* 2003; 846: 24 1865-1904.
80. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. *N Engl J Med* 2003; 347: 1825-1833.
81. The AFFIRM Investigators. Baseline characteristics of patients with atrial fibrillation: the AFFIRM Study. *Am Heart J* 2002; 143:991-1001.
82. Sesselbert HW, Moss AJ, **Steinberg JS**, Carroll E, Zareba W, Daubert J, Huang DT. Factors associated with ventricular inducibility in the MADIT-II study population. *Am J Cardiol* 2003; 91: 1002-1004.
- 83.* DeRose JJ, Ashton RC, Belsley S, Swistel DG, Vloka M, Ehlert F, Shaw R, Sackner Bernstein J, Hillel Z, **Steinberg JS**. Robotically assisted left ventricular epicardial lead implantation for biventricular pacing. *J Am Coll Cardiol* 2003; 41: 1414-1419.
- 84.* Maniar PB, **Steinberg JS**. Evolving concepts in the treatment of atrial fibrillation. *Curr Cardiol Reports* 2003; 5: 358-363.
- 85.* Babaev A, Suma V, Tita C, **Steinberg JS**. Recurrence rate of atrial flutter after initial presentation in patients on drug treatment. *Am J Cardiol* 2003; 92: 1122-1124.
- 86.* Maniar PB, Balcetyte-Harris N, Tamis J, **Steinberg JS**. Intravenous versus oral beta-blockers for prevention of post-cabg atrial fibrillation in high-risk patients identified by signal-averaged ecg: lessons of a pilot study. *CEPR* 2003; 7:158-161.
- 87.* **Steinberg JS**, Maniar PB, Higgins SL, Whiting SL, Meyer DB, Dubner S, Shah AH, Huang DT, Saxon LA. Noninvasive assessment of the biventricular pacing system. *ANE* 2004; 9:58-70.
- 88.* **Steinberg JS**. Atrial fibrillation: an emerging epidemic? *Heart* 2004; 90:239-240.
- 89.* **Steinberg JS**, Sadaniantz A, Kron J, Krahn A, Denny DM, Daubert J, Campbell B, Havranek E, Murray K, Olshansky B, O'Neill G, Sami M, Schmidt S, Storm R, Zabalgoitia M, Miller J, Chandler M, Nasco EM, Greene HL, and the AFFIRM Investigators. Analysis of cause-specific mortality of the Atrial Fibrillation Investigation Follow-up Investigation of Rhythm Management Trial. *Circulation* 2004;109:1973-1980.

PUBLICATIONS (cont'd)

- 90.* **Steinberg JS.** Postoperative atrial fibrillation: a billion-dollar problem. *J Am Coll Cardiol* 2004; 43:1001-1003.
- 91.* **Steinberg JS, DeRose JJ.** The rationale for epicardial lead implantation for cardiac resynchronization devices. *PACE* 2003;26:2211-2212.
- 92.* **Steinberg JS, Sadaniantz A, Kron J, Krahn A, Denny DM, Daubert J, Campbell B, Havranek E, Murray K, Olshansky B, O'Neill G, Sami M, Schmidt S, Storm R, Zabalgoitia M, Miller J, Chandler M, Nasco EM, Greene HL, and the AFFIRM Investigators.** Response to Letter to the Editor. *Circulation* 2004; 110: E307-E308.
93. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass D, DeMarco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM, for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. *N Engl J Med* 2004; 350:2140-50.
- 94.* **Steinberg JS, Arshad A, Kowalski M, Kukar A, Suma V, Vloka M, Ehlert F, Herweg B, Donnelly J, Philip J, Reed G, Rozanski A.** Increased incidence of life-threatening ventricular arrhythmias in implantable defibrillator patients after the world trade center attack. *J Am Coll Cardiol* 2004; 44:1261-1264.
- 95.* Shedd OL, Sears Jr. SF, Harvill JL, Arshad A, Conti JB, **Steinberg JS, Curtis AB.** The world trade center attack: Increased frequency of defibrillator shocks for ventricular arrhythmias in patients living remotely from New York City. *J Am Coll Cardiol* 2004; 44:1265-1267.
- 96.* Irvanian S, Arshad A, **Steinberg JS.** Role of electrophysiologic studies, signal-averaged electrocardiography, heart rate variability, T-wave alternans, and loop recorders for risk stratification of ventricular arrhythmias. *AJGC* 2005; 14: 16-19.
97. Dorian P, Borggrefe M, Al-Khalidi HR, Hohnloser SH, Brum JM, Tatla DS, Brachmann J, Myerburg RJ, Cannom DS, van der Laan M, Holroyde MJ, Singer I, Pratt CM, and the SHIELD Investigators. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. *Circulation* 2004;110:3646-3654.
- 98.* Herweg B, Sichrovsky T, Polosajian L, Vloka M, Rozenshtein A, **Steinberg JS.** Anatomic substrate, procedural results, and clinical outcome of ultrasound-guided left atrial-pulmonary vein disconnection for treatment of atrial fibrillation. *Am J Cardiol* 2005;95:871-875.
- 99.* Herweg B, Sichrovsky T, Polosajian L, Rozenshtein A, **Steinberg JS.** Hypertension and hypertensive heart disease are associated with increased ostial pulmonary vein diameter. *J Cardiovasc Electrophysiol* 2005;16:2-5.
- 100.* Maleki K, Mohammadi R, Hart D, Cotiga D, Farhat N, **Steinberg JS.** Intracardiac ultrasound detection of thrombus on transseptal sheath: Incidence, treatment, and prevention. *J Cardiovasc Electrophysiol* 2005;16:561-565.

PUBLICATIONS (cont'd)

- 101.* **Steinberg JS**, Fischer A, Wang P, Schuger C, Daubert J, McNitt S, Andrews M, Brown M, Hall WJ, Zareba W, Moss AJ; for the MADIT II Investigators. The clinical implications of cumulative right ventricular pacing the Multicenter Automatic Defibrillator Implantation Trial II. *J Cardiovasc Electrophysiol* 2005;16:359-365.
- 102.* **Steinberg JS**, Arshad A, Rozanski A, Shedd OL, Curtis AB. [Reply Letter to the Editor] *J Am Coll Cardiol* 2005;45:1732-1733.
- 103.* Herzog E, Fischer A, **Steinberg JS**. The rate control, anticoagulation therapy, and electrophysiology/antiarrhythmic medication pathway for the management of atrial fibrillation and atrial flutter. *Crit Path Card* 2005;4:121-126.
104. Sharma AD, Rizo-Patron C, Hallstrom AP, O'Neill GP, Rothbart G, Martins JB, Roelke M, **Steinberg JS**, Greene HL, DAVID Investigators. Percent right ventricular pacing predicts outcomes in the DAVID trial. *Heart Rhythm* 2005;2:830-834.
105. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski R, Troutman C, Anderson J, Johnson G, McNulty ST, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure (SCD-HeFT) Investigators. *N Engl J Med* 2005;352:225-237.
- 106.* Joshi S, Herzog E, DeRose Jr. JJ, Kasaryan H, Singh V, **Steinberg JS**. Images in Cardiology: Acute anterior wall myocardial infarction in a young male with hypertrophic cardiomyopathy and myocardial bridging. *Clin Cardiol* 2005;28:491.
107. Doshi RN, Daoud EG, Fellows C, Turk K, Duran A, Hamdan MH, Pires LA, PAVE Study Group. Left ventricular-based cardiac stimulation Post AV nodal ablation Evaluation (The PAVE Study). *J Cardiovasc Electrophysiol* 2005;16:1160-1165.
108. Carson P, Anand I, O'Connor C, Jaski B, **Steinberg JS**, Lwin A, Lindenfeld J, Ghali J, Barnet JH, Feldman AM, Bristow MR. Mode of death in advanced heart failure. The comparison of medical pacing, and defibrillation therapies in heart failure (COMPANION) trial. *J Am Coll Cardiol* 2005;46:2329-2334.
- 109.* Joshi S, **Steinberg JS**, Ashton Jr. RC, Balaram S, Fischer A, DeRose JJ. Follow-up of robotically assisted left ventricular epicardial leads for cardiac resynchronization therapy. *J Am Coll Cardiol* 2005;46:2358-2359.
110. DeRose Jr. JJ, Balaram S, Ro C, Swistel DG **Steinberg JS**, Joshi S, Ashton Jr. RC. Midterm follow-up of robotic biventricular pacing demonstrates excellent lead stability and improved response rates. *Innovations* 2006;2:1-6.
- 111.* Bangalore S, Petre L, Herweg B, Sichrovsky T, Vragel S, **Steinberg JS**, Chaudhry F. Cardioversion in patients with left ventricular thrombus is not associated with increased thromboembolic risk. *J Am Soc Echocardiogr* 2006;19:438-440.
112. Vyas AK, Guo H, Moss AJ, Olshansky B, McNitt SA, Hall WJ, Zareba W, **Steinberg JS**, Fischer A, Ruskin J, Andrews ML. Reduction in ventricular tachyarrhythmias with statins in the multicenter automatic defibrillator implantation trial (MADIT)-II. *J Am Coll Cardiol* 2006;47:769-773.

PUBLICATIONS (cont'd)

- 113.* **Steinberg JS**, Levitt H. Magnetocardiography throws its hat in the ring. *J Cardiovasc Electrophysiol* 2006;17:402-404.
- 114.* Tamis-Holland JE, Kowalski M, Rill V, Firoozi K, **Steinberg JS**. Patterns of atrial fibrillation after coronary artery bypass surgery. *ANE* 2006;11:139-144.

CASE REPORTS

1. * Martin LW, Wasserman AG, Goldstein H, **Steinberg JS**, Mills M, Katz RJ. Multiple cardiac myxomas with multiple recurrences: unusual presentation of a "benign" tumor. *Ann Thor Surg* 1987; 44:77-78.
2. * Cook JR and **Steinberg JS**. An incessant form of junctional ectopic tachycardia in an adult responsive to a class 1C agent. *Am Heart J* 1991; 122:1487-1489.
3. * Sadanandan S, **Steinberg JS**, Siegel DM. Ischemic skin necrosis: a complication of implantable cardioverter defibrillator therapy. *Heart Web* (Internet - <http://www.webaxis.com/heartweb/0397/icd0001.htm>).
4. * Vloka ME, Tamis JE and **Steinberg JS**. Neurally mediated syncope in two patients with extracardiac pathology. *Arch Int Med* 1999;159(6):625-27.

CHAPTERS, REVIEWS, MONOGRAPHS AND TEXTBOOKS

1. Antunes ML, Spotnitz HM, **Steinberg JS**, Bigger JT, Jr. Measurement of ejection fraction during intraoperative electrophysiologic testing of the automatic implantable cardioverter-defibrillator. *Arrhythmia Clinic* 1988;5:13-22.
2. Bigger JT, Jr and **Steinberg JS**. Risk stratification for arrhythmic death after myocardial infarction. In: "Cardiac Pacing and Electrophysiology," edited by El Sherif N and Samet P, W.B. Saunders Company, Philadelphia, 1990, pp. 303-323.
3. * **Steinberg JS**, Freedman RA, Bigger JT, Jr. Antiarrhythmic during treatment and the signal averaged electrocardiogram. In: "High Resolution Electrocardiography," edited by El-Sherif N and Turitto G, Futura Publishing Company, Mt. Kisco, NY, 1991, pp 569-590.
4. * Lander P, **Steinberg JS**, Bigger JT, Jr., Berbari EJ. Signal-averaging of ventricular late potentials using Holter recordings. In: "Computers in Cardiology," IEEE Computer Society Press, Los Angeles, CA, 1988, pp. 377-380.
5. * **Steinberg JS** and Lander P. Noise reduction and the signal-averaged ECG. In: "Signal-Averaged Electrocardiography," edited by Gomes JA, Kluwer Academic Publishers, Dordrecht, The Netherlands, 1993, pp.203-220.
6. * **Steinberg JS** and Ehlert FA. The P-wave signal-averaged ECG. In: "Noninvasive Electrocardiology: Clinical Aspects of Holter Monitoring", edited by Moss AJ and Stern S, WB Saunders Ltd, London, UK, 1996, pp 255-272.
7. * **Steinberg JS** and Berbari EJ. Signal-averaged electrocardiography: update on clinical applications. *J Cardiovasc Electrophysiol* 1996;7:972-988.
8. * Ehlert FA and **Steinberg JS**. The P wave signal-averaged ECG. *J Electrocard* 1996;28:33-38.
9. * Tamis J and **Steinberg JS**. Update on the clinical use of the signal-averaged electrocardiogram. *ANE* 1996;1:316-333.
- 10.* Vloka ME and **Steinberg JS**. QT dispersion: current and future clinical role. *J Inv Cardiol* 1996;8:363-369.
- 11.* **Steinberg JS**, ed. "Atrial Fibrillation After Cardiac Surgery". Kluwer Academic Publishers, Norwell, MA, 1999.
12. * Lewis RJ and **Steinberg JS**. Oral antiarrhythmic drugs used for arrhythmia prevention. *Card Electrophys Rev* 1998;2:182-185.
- 13.* Berbari EJ and **Steinberg JS**, eds. "A Practical Guide to the Use of the High Resolution Electrocardiogram." Futura Publishing Co., Armonk, NY 2000.
14. * Ehlert FA, Narula DD and **Steinberg JS**. Risk factors for development of atrial fibrillation. In: "Atrial Fibrillation After Cardiac Surgery," edited by Steinberg JS, Kluwer Academic Publishers, Norwell, MA 1999, pp 51-80.

CHAPTERS, REVIEWS, MONOGRAPHS AND TEXTBOOKS (cont'd)

15. * Tamis JE and **Steinberg JS**. The impact of atrial fibrillation on hospital length of stay. In: "Atrial Fibrillation After Cardiac Surgery," edited by Steinberg JS, Kluwer Academic Publishers, Norwell, MA 1999, pp 81-93.
16. * Lewis RJ and **Steinberg JS**. Nonpharmacologic treatment of postoperative atrial fibrillation. In: "Atrial Fibrillation After Cardiac Surgery," edited by Steinberg JS, Kluwer Academic Publishers, Norwell, MA 1999, pp 119-132.
17. * Narula DD and **Steinberg JS**. Atrial fibrillation after noncardiac surgery. In: "Atrial Fibrillation After Cardiac Surgery," edited by Steinberg JS, Kluwer Academic Publishers, Norwell, MA 1999, pp 141-164.
18. * **Steinberg, JS** and Shah AI. Heart block. In: "Conn's Current Therapy", edited by Rakel RE and Bope ET, W.B. Saunders Co, Philadelphia, PA .
19. * **Steinberg JS**, guest editor. "QT Dispersion". Prog CV Dis 2000;42.
20. * Carnendran L and **Steinberg JS**. Does an open infarct-related artery after myocardial infarction improve electrical stability? Prog CV Dis 2000;42:439-454.
- 21.* Arfaei A and **Steinberg JS**. Reimbursement issues for noninvasive testing. Cardiac Electrophysiol Rev 2000;4:129-129.
- 22.* Frankenberger O and **Steinberg JS**. Beta-blockers and amiodarone for the primary prevention of sudden cardiac death. Current Cardiology Report 1999, I, 274-281.
- 23.* Herweg B and **Steinberg JS** . Oral antiarrhythmic drugs used for arrhythmia prevention. Card Electrophys Rev 2000;4:255-261.
- 24.* Perera R and **Steinberg JS**. The signal averaged P-wave. In: "Advances in Noninvasive Electrocardiographic Monitoring Techniques," edited by Osterhues H-H, Hombach V, Moss AJ, Kluwer Academic Publishers, Dordrecht, The Netherlands 2000, pp 89-97.
25. * Dorbala S and **Steinberg JS**. Signal averaging of the P wave. In "Noninvasive Electrocardiology in Clinical Practice," edited by Zareba W, Maison-Blanche P, Locati EH, Futura Publishing Co., Inc., Armonk, NY 2001, pp 31-47.
- 26.* **Steinberg JS**. Right heart hemodynamics/heart rate log variability. In "Resynchronization Therapy for Heart Failure", edited by Saxon LA and De Marco T. www.naspe.org/professional_education, 2004.
- 27.* Joshi S and **Steinberg JS**. The therapeutic role of the implantable cardioverter defibrillator in arrhythmogenic right ventricular dysplasia. First International Symposium on Arrhythmogenic Right Ventricular Dysplasia, www.arvd-symposium.org, 2005.
- 28.* Levitt HL, Skylar E, **Steinberg JS**. Mortality in atrial fibrillation: a review of the overall and cause-specific causes of mortality in atrial fibrillation. ISHNE AF World-Wide Internet Symposium, www.af-symposium.org, 2005.

CHAPTERS, REVIEWS, MONOGRAPHS AND TEXTBOOKS (cont'd)

- 29.* DeRose JJ, **Steinberg JS**. Surgical approaches to epicardial left ventricular lead implantation for biventricular pacing. In "Cardiac Resynchronization Therapy," edited by Yu CM, Hayes DL, Auricchio A, Blackwell Futura Publishing Co., Malden, MA 2006, pp 227-236.
- 30.* **Steinberg JS**. Heart failure: Atrial Fibrillation. ISHNE Heart Failure Worldwide Internet Symposium, www.hf-symposium.org, 2006.
- 31.* Arshad A, Iravani S, **Steinberg JS**. Pacing therapy for acute decompensated heart failure. In "Acute Decompensated Heart Failure" edited by O'Connor CM, Stough WG, Gheorghiade M, Adams Jr. KF, Taylor & Francis Group, Boca Raton, FL 2006, pp 371-386.

NON-PEER REVIEWED PUBLICATIONS

1. * **Steinberg JS**, Katz RJ. Diltiazem for control of ventricular response. *Cardiol Board Rev* 1987;9:100-111.
2. * **Siu D** and **Steinberg JS**. Predicting arrhythmic events after acute myocardial infarction using the signal-averaged electrocardiogram. *Cardiol Board Rev* 1992; 9:39-51.
3. * **Ehlert FA**, and **Steinberg JS**. Signal-averaging of the surface p-waves in the prediction and management of patients with atrial fibrillation. *Primary Cardiol* 1994;20:43-53.
4. * **Steinberg JS**. Therapeutic options in cardiac arrhythmias. *Cortlandt Forum* 1993; 6:136-144.
5. * **Bhan RM**, **Ehlert FA** and **Steinberg JS**. Use of the signal-averaged electrocardiogram in patients with unexplained syncope. *Cardiol Board Rev* 1995; 12:37-40.
6. * **Steinberg JS** and **Ehlert FA**. The expanding role of radiofrequency catheter ablation. *Choices in Cardiol* 1995;9:38-41.

ABSTRACTS

1. Reitano J, King M, Cohen H, El-Sadr W, Rubler S, **Steinberg JS**, Fisher V. Cardiac function in patients with acquired immune deficiency syndrome or AIDS prodrome. *J Am Coll Cardiol* 1984;3:525A.
- 2.* **Steinberg JS**, Katz RJ, Bren GB, Buff L, Varghese PJ, Wasserman AG, Ross AR. Efficacy of oral diltiazem to control rest and exercise ventricular response in atrial fibrillation. *J Am Coll Cardiol* 1986; 7:157A.
- 3.* **Steinberg JS**, Cohen AJ, Wasserman AG, Ross AR, Cohen P. Cardiac rhythm monitoring during doxorubicum infusion: absence of acute arrhythmogenicity. *Proc Am Soc Clin Onc* 1986;5:35.
- 4.* **Steinberg JS**, Bigger JT Jr, Bernstein F. Results of signal averaged ECG are dependent upon endpoint of noise reduction. *Circulation* 1987; 76(Supp IV):342A.
- 5.* **Steinberg JS**, Bigger JT Jr, Livelli FD, Spotnitz HM. Recurrence of ventricular tachyarrhythmias in patients with automatic implantable defibrillators and no antiarrhythmic therapy. *Circulation* 1987;76(Supp IV):461A.
6. Antunes ML, Spotnitz HM, Livelli FD Jr, **Steinberg JS**, Bigger JT Jr. Effect of electrophysiologic testing on ejection fraction during cardioverter defibrillator implants. *Circulation* 1987; 76(Supp IV):310A.
- 7.* **Steinberg JS**, Freedman RA, for the ESVEM investigators. The signal averaged ECG does not predict drug efficacy in sustained ventricular arrhythmias. *Circulation* 1987;76(Supp IV):344A.
- 8.* **Steinberg JS**, Michelson K, Reiffel JA, Livelli F, Gliklich J, Bigger JT, Jr. Use of the signal averaged electrocardiogram to predict electrophysiologic study results in unexplained syncope. *J Am Coll Cardiol* 1988;11:183A.
- 9.* **Steinberg JS**, Lander P, Bigger JT, Jr., Berbari EJ. Signal averaging directly from Holter tapes - results of a new technique. *Circulation* 1988;78(Supp II):11-200.
10. Freedman RA, Fuller MS, **Steinberg JS**, for the ESVEM investigators. Effect of antiarrhythmic drugs on frequency-domain parameters of signal averaged ECG. *J Am Coll Cardiol* 1989;13:191A.
- 11.* **Steinberg JS**, Smith R, Bigger JT, Jr., Damm CJ. Determinants of the signal averaged ECG after myocardial infarction: Relationship to infarct size and site in an experimental canine model. *PACE* 1989;12:665.
12. Freedman RA, Fuller MS, **Steinberg JS**, Barton DD. Comparison of time domain and frequency domain parameters of signal-averaged ECG in identifying cardiac patients with ventricular tachycardia. *Circulation* 1989;80:II-636.
13. Freedman RA, **Steinberg JS**, Moreno FL, Barton DD. Sotalol-induced changes in signal-averaged QRS duration: relation to efficacy in preventing ventricular tachycardia induction. *Circulation* 1989;80:II-36.

ABSTRACTS (cont'd)

14. * **Steinberg JS**, Sugalski JS, Haratonik K, Boxer N. Cardiac rhythm precipitating automatic implantable cardioverter defibrillator discharge in outpatients: observations from transtelephonic recordings. *Circulation* 1989;80:II-530.
15. * **Steinberg JS**, Bigger JT, Jr., Damn CJ. Predictors of ventricular tachycardia after experimental myocardial infarction: use of the signal averaged ECG and infarct size. *Circulation* 1989;80:II-36.
16. The CAST Investigators. Increased mortality due to encainide and flecainide in the Cardiac Arrhythmia Suppression Trial (CAST). *Circulation* 1989; 80:II-428.
17. * **Steinberg JS**, Regan A, Salvator DE, Fosina M, Sciacca RR, Bigger JT, Jr. Predicting arrhythmic events after myocardial infarction: results of a prospective study using the signal-averaged ECG. *J Am Coll Cardiol* 1990; 15:197A.
18. Freedman RA, **Steinberg JS**, Friday KJ, Rawling DA, Barton DD. Detection of QRS prolongation caused by antiarrhythmic drugs: increased sensitivity of signal-averaged ECG compared to standard ECG, and relation to selective prolongation of late potentials. *PACE* 1990;13:542.
- 19.* Wechsler ME, **Steinberg JS**, Giardina EGV. Time course of ethmozine effect on the signal-averaged and 12-lead electrocardiograms: insights into mechanism of action. *PACE* 1990, 13:523
- 20.* Guidera SA and **Steinberg JS**. The atrial late potential - association with paroxysmal or prior atrial fibrillation. *Circulation* 1990;82:III-752.
21. Wyse DG, Hallstrom A, McBride RD, Cohen JD, **Steinberg JS**, Mahmarian J, Davies R for the CAST Investigators. Mortality in Cardiac Arrhythmia Suppression Trial (CAST) patients not randomized to double-blind therapy. *Circulation* 1990; 82:III-198.
- 22.* Bloomfield DM, Snyder JE, **Steinberg JS**. Spectro-temporal mapping for risk of sustained ventricular arrhythmias: quantitative analysis in post-MI patients. *J Am Coll Cardiol* 1991; 17:241A.
- 23.* **Steinberg JS**, Prystowsky EN, Freedman RA, Moreno F, Katz R, Kron J, Regan A. Usefulness of the signal-averaged ECG for predicting inducible ventricular tachycardia in patients with unexplained syncope. *J Am Coll Cardiol* 1991; 17:98A.
- 24.* O'Hara MJ, Homma S, Regan A, **Steinberg JS**. Conduction delay in the signal-averaged electrocardiogram of hypertensive patients is related to left ventricular mass. *J Am Coll Cardiol* 1991; 17:72A.
25. Freedman RA, **Steinberg JS** for the ESVEM investigators. Prolongation of late potentials by antiarrhythmic drugs correlates with prolongation of ventricular tachycardia cycle length. *J Am Coll Cardiol* 1991; 17:197A.
- 26.* Katz J, Czegledy F, Boxt LM, **Steinberg JS**. Fractal analysis of signal-averaged ECG's in patients with a history of sustained ventricular tachycardia. *PACE* 1991;14:747.

ABSTRACTS (cont'd)

27. Katz RJ, **Steinberg JS**, Josephson RA, Horowitz L, for the CAST investigators. Atrial proarrhythmia in cardiac arrhythmia suppression trial (CAST). *Circulation* 1991; 84: II-126.
- 28.* Bloomfield DM, Lander P, **Steinberg JS**. Changes in the frequency domain of the signal-averaged electrocardiogram post-myocardial infarction. *J Am Coll Cardiol* 1992; 19:43A.
- 29.* Jadonath R and **Steinberg JS**. Does transient myocardial ischemia alter the signal-averaged electrocardiogram? *PACE* 1992; 15:548.
- 30.* **Steinberg JS**, Pinsky DJ, Regan A, Rose EA. Risk of mortality for patients awaiting cardiac transplantation: is the signal-averaged ECG a useful predictor? *PACE* 1992; 15:581.
- 31.* **Steinberg JS**, Prystowsky EN, Freedman RA, Moreno F, Katz R, Kron J, Regan A, Sciacca RR. Incremental value of sequential noninvasive testing including signal-averaged electrocardiography to predict ventricular tachycardia in patients with unexplained syncope. *Circulation* 1992; 86:I-389.
- 32.* Siu D, **Steinberg JS**, Jadonath R, Van Etten P. Inappropriate sinus tachycardia after radiofrequency ablation of the atrioventricular nodal fast pathway. *Circulation* 1992; 86:I-191.
33. Greenberg HM, Hochman JS, **Steinberg JS**, Mitchell LB, Echt DS, Peters RW, Barker AH, Greene HL, Dwyer ED and CAST Investigators. Interaction of ischemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I. *Circulation* 1992; 86:I-315.
- 34.* **Steinberg JS**, Hochman JS, Morgan CD, Dorian P, Theroux P, Topol EJ, Armstrong PW, and LATE Ancillary Investigators. The effects of thrombolytic therapy administered 6-24 hours after myocardial infarction on the signal-averaged ECG: results of a multicenter trial. *J Am Coll Cardiol* 21:225A.
- 35.* Zelenkofske S, Gelernt M, Wong S-C, Menchavez E, **Steinberg JS**. The value of p-wave signal-averaged ECG for predicting atrial fibrillation after open heart surgery; a prospective study. *J Am Coll Cardiol* 1992; 21:181A.
36. Morgan CD, Hochman JS, Burns RJ, Freeman MR, **Steinberg JS**, Theroux P, Topol EJ, Armstrong PW, for the LATE Ancillary Investigators. The effect of late thrombolytic therapy on left ventricular function following acute myocardial infarction. *J Am Coll Cardiol* 1992; 21:224A.
- 37.* Bloomfield DM, Freedman RA, **Steinberg JS**. Slowed conduction with arrhythmic drugs reduces high frequency energy of the signal-averaged ECG. *PACE* 1993; 16:913.
- 38.* **Steinberg JS** and Korenstein D. Comparison of techniques for analysis of the P-wave signal-averaged ECG. *Circulation* 1993; 88:I-311.
- 39.* Zelenkofske S, Brown E, Mogtader A, Menchavez E, **Steinberg JS**. Prolonged SAECG P-wave duration is not due to atrial enlargement. *Circulation* 1993; 88:I-311.

ABSTRACTS (cont'd)

- 40.* Hochman JS, Morgan CD, **Steinberg JS**, Burns RJ, Freeman MR, Dorian P, Armstrong PW. Filtered QRS duration and left ventricular volume post MI are positively related; results of a randomized controlled trial of late thrombolysis. *Circulation* 1993; 88:I-312.
- 41.* Jadonath RL, Siu D, Zadeh B, Swistel D, **Steinberg JS**. First occurrence of sustained ventricular tachycardia soon after cardiac surgery. *Chest* 1993; 104:1665.
- 42.* Zelenkofske S, Siu D, Van Etten P, Menchavez-Tan E, Ehlert F, **Steinberg JS**. Bretylium tosylate is ineffective for ventricular tachycardia. *J Am Coll Cardiol* 1994;23:35A.
- 43.* **Steinberg JS**, Ehlert FA, Menchavez-Tan E. Immediate and short-term reproducibility of the P-wave signal-averaged electrocardiogram. *J Am Coll Cardiol* 1994; 23:252A.
- 44.* Zelenkofske S, Van Etten P, **Steinberg JS**. Can implantable cardioverter defibrillator patients be followed off antiarrhythmic drugs? *PACE* 1994; 17:834
- 45.* Hillel Z, Ehlert FA, Mogtader AH, **Steinberg JS**. Lack of evidence for atrial stunning after DC shock in patients in normal sinus rhythm undergoing ICD insertion: a study using TEE. *J Am Coll Cardiol* 1994; 25: 264A.
- 46.* Hutchinson LA, Moreno FL, Ehlert FA, **Steinberg JS**. A new noninvasive test to predict inducible ventricular tachycardia in patients with unexplained syncope: QT dispersion. *J Am Coll Cardiol* 1994; 25: 389A.
- 47.* Hutchinson LA, Ehlert FA, Menchavez-Tan E, **Steinberg JS**. Towards a better understanding of the development of atrial fibrillation after cardiac surgery: risk factor analysis in a large prospective study. *J Am Coll Cardiol* 1994; 25: 318A.
- 48.* Pinsky DJ, Sciacca R, **Steinberg JS**. QT dispersion measured at the time of wait listing is a powerful predictor of who will die awaiting heart transplantation. *J Am Coll Cardiol* 1994; 25: 142A.
49. Brooks MM, Jenkins LS, Schron EB, **Steinberg JS**, Cross JA, Paeth DS. "Quality of life data collected before and after randomization. *Cont Clin Trials* 1995;16:131-132S.
- 50.* **Steinberg JS**, Lawal O, Gavani S, Ehlert F, Gagnon J. Characteristics of minority patients with ventricular arrhythmias and implantable cardioverter-defibrillators: implications for clinical trial enrollment. *PACE* 1995; 18:944.
- 51.* Prasher S, Ehlert FA, Zelenkofske S, Menachavez-Tan E, **Steinberg JS**. First episode of sustained ventricular tachycardia in the recovery period after coronary artery bypass surgery: results of a prospective analysis. *PACE*; 18:849.
52. Lander P, Berbari EJ, Lazzara R, Gomis P, **Steinberg JS**. Analysis of intra-QRS late potentials improves the predictive value of the signal-averaged ECG. *PACE* 1995; 18:796.
53. AVID Investigators. Patient enrollment in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study - pilot phase. *PACE* 1995; 18:799.

ABSTRACTS (cont'd)

54. AVID Investigators. Characteristics of patients enrolled in the Pilot phase of the antiarrhythmics Versus Implantable Defibrillators (AVID) Study. *PACE* 1995; 18:900.
- 55.* Vloka ME, Hutchinson LA, Ehlert FA, Mogtader AH, **Steinberg JS**. Abnormal QT dispersion in patients with mitral valve prolapse. *Circulation* 1995;92:I-214.
- 56.* Keller AM, **Steinberg JS**, Abreu JE, Gopal AS, King DL. Signal-averaged P-wave duration: relation to atrial volume as assessed by cine magnetic resonance imaging. *Circulation* 1995;92:I-407.
- 57.* Hutchinson LA, Cohen AJ, Menchavez-Tan E, Abis N, **Steinberg JS**. Does radiofrequency ablations induce a pre thrombotic state? *J Am Coll Cardiol* 1996;27:211A.
- 58.* Carrillo LE, **Steinberg JS**, Kutalek SP, Berkman K, Akiyama T, Coromilas J, Tullo NG. Significant ICD event rate in patients with unexplained syncope and inducible ventricular tachycardia. *J Am Coll Cardiol* 1996;27:402A.
- 59.* Luchsinger JA, and **Steinberg JS**. Reversal of cardiomyopathy after successful radiofrequency catheter ablation. *PACE* 1996;19:635.
- 60.* Tamis JE, and **Steinberg JS**. Atrial fibrillation is the only modifiable factor that lengthens hospital stay after coronary artery bypass surgery. *PACE* 1996;19:622.
61. Pinski SL, **Steinberg JS**, Goodman S, Helguera ME, Connors S, Song Q, Lawson WT, Gates K, Wagner GS. Lack of agreement in QT dispersion measurement by 3 different methods. *PACE* 1996;19:667.
- 62.* Heller SS, Ormont MA, Lidagoster LC, **Steinberg JS**. Psychiatric outcomes following automatic implantable cardiac defibrillator implantation. *PACE* 1996;19:606.
- 63.* Gaur A and **Steinberg JS**. New onset sustained ventricular tachycardia after coronary artery bypass surgery: strong evidence implicating reperfusion of infarct zone. *PACE* 1996;19:590.
- 64.* Chandrasekaran S, **Steinberg JS**, Slater JN, Morgan CD, Cameron AC, Palazzo AM, Vloka ME, Hochman JS. Infarct artery patency after myocardial infarction is associated with an improved signal averaged electrocardiogram. *Circulation* 1996;94:I-20.
- 65.* Ehlert FA, Gaur A, **Steinberg JS**. Correlation of the P wave signal averaged electrocardiogram to intracardiac atrial conduction. *Circulation* 1996;94:I-70.
- 66.* Hutchinson LA, Luchsinger JA, Carnendran L, Slater JN, Shanahan AJ, **Steinberg JS**. The effect of acute ischemia on QT dispersion. *Circulation* 1996;94:I-451.
- 67.* Carrillo LE, Suster B, O'Sullivan M, **Steinberg JS**. High attenuation abnormalities on chest CT scan; a marker of amiodarone pulmonary toxicity. *Am Coll Cardiol* 1997;29:516A.
68. Amar D, Roistacher N, **Steinberg JS**, Zhang H. Value of signal-averaged P-wave duration in predicting atrial fibrillation after thoracic surgery. *J Am Coll Cardiol* 1997;29:191A.

ABSTRACTS (cont'd)

69. Zareba, W, **Steinberg JS**, Moss AJ, Heo M, Marcus FI for the MADIT Investigators. Signal-averaged ECG in the Multicenter Automatic Implantation Trial (MADIT). *J Am Coll Cardiol* 1997;29:31A.
70. Hadzic A, Vloka ME, Mogtader AH, Hillel Z, **Steinberg JS**. Abnormal QT dispersion in patients with mitral valve prolapse: correlation with echocardiographic findings. *Anes Analg* 1997;84, SCA64.
- 71.* Hutchinson LA, **Steinberg JS**. Use of ultra-rapid subthreshold stimulation to localize slow pathway ablation site. *PACE* 1997;20:134A.
- 72.* Ehlert FA, Hutchinson LA, Cossu S, **Steinberg JS**. Changes in conduction properties of residual slow pathway function mark recurrence-free success in catheter ablation of AV nodal reentrant tachycardia via the posterior approach. *PACE* 1997;20:138A.
- 73.* Narula DD, Wali AU, Vloka ME, Menon V, **Steinberg JS**. Prolonged QT dispersion correlates with appropriate implantable cardioverter-defibrillator therapy. *Circulation* 1997; 4008:I-715.
- 74.* **Steinberg JS**, Ehlert FA, Cannom DS, Marinchak RA, Halperin BD, Herre JM, Gonzalez MD, Anderson J, Mitchell LB, Luceri R, Ledingham r, Renfroe EG. Dilated cardiomyopathy vs coronary artery disease in patients with VT/VF: differences in presentation and outcome in the antiarrhythmics versus implantable defibrillators (AVID) registry. *Circulation* 1997;4011:I-715.
- 75.* Narula DD, **Steinberg JS**, Ehlert FA, Vloka ME, Novak BJ. Actuarial survival of CPI epicardial defibrillation and rate sensing leads. *Circulation* 1997;3887: I-694.
76. Jenkins LS, **Steinberg JS**, Cook JR, Schron EB, Friedman PL, Bosworth-Farrel S, Qing Y. Quality of life in patients enrolled in the antiarrhythmics versus implantable defibrillators (AVID) trial. *Circulation* 1997;2451:I-439.
77. Zareba W, Moss AJ, **Steinberg JS**. QT duration and dispersion do not predict outcome in post-infarction patients with inducible ventricular tachycardia: experience from the Multicenter Automatic Defibrillator Implantation Trial. *Circulation* 1997;423:I-77.
- 78.* Vloka ME, Sadurski R, Narula DD, Menon V, Ehlert FA, **Steinberg JS**. Age dependent atrial activation delay: observations using the P-wave signal averaged electrocardiogram. *J Am Coll Cardiol* 1998;31:47A.
- 79.* Tamis JE, Vloka ME, Malhotra S, Mindich BP, **Steinberg JS**. Atrial fibrillation is common after minimally invasive direct coronary artery bypass surgery. *J Am Coll Cardiol* 1998;31:118A.
- 80.* Narula DD, **Steinberg JS**, Ehlert FA, Vloka ME, Zareba W for the MADIT investigators. Electrophysiology study characteristics: correlation with cardiac death and defibrillator shocks in the multicenter automated defibrillator implantation trial. *J Am Coll Cardiol* 1998;31:159A.
- 81.* Vloka ME, Sharma A, Narula DD, Ehlert FA, **Steinberg JS**. Do specialists make a difference in the management of unexplained syncope? *J Am Coll Cardiol* 1998;31:363A.

ABSTRACTS (cont'd)

- 82.* **Steinberg JS**, Martins JB, Domanski M, Foster P, Goldner B, Greene HL, Menchavez-Tan E, Rozo-Patron C, Russo A, Tullo N, Moore R, Hallstrom A, The AVID Investigators. Antiarrhythmic drug use in the implantable defibrillator arm of the antiarrhythmics vs. implantable defibrillators (AVID) study. *J Am Coll Cardiol* 1998;31:514A.
- 83.* DeRose JJ, Ashton RC, Belsley S, Swistel DG, Vloka M, Ehlert F, Shaw R, Sackner-Bernstein J, Hillel Z, **Steinberg, JS**. Robotically assisted left ventricular epicardial lead implantation for biventricular pacing. *J Am Coll Cardiol* 2003; 41: 1414-19.
- 84.* Narula DD, Kaddaja RM, Wali AU, Vloka ME, Lewis R, **Steinberg JS**. Relationship of QT dispersion to mode of onset of spontaneous ventricular tachycardia in patients with implantable defibrillators. *PACE* 1998;21:704A.
85. Schron E, Jenkins LS, Qing Y, Cook J, Kutalek S, **Steinberg JS**. and the AVID Investigators. Quality of life in the antiarrhythmics versus implantable defibrillators (AVID) trial. *Arch Mal Coeur* 1998; 91:60-6.
- 86.* Vloka ME, Wali Au, Narula DD, Ehlert FA, **Steinberg JS**. Use of QT dispersion for risk stratification after acute myocardial infarction is hampered by high day to day variability. *Circulation* 1998;98:I-81A.
- 87.* Narula DD, Jaber WA, Widmer AJ, Ehlert FA, Vloka ME, **Steinberg JS**. Is there a gender bias in selection of dual chamber and rate responsive pacemakers? *J Am Coll Cardiol* 1999;33:154A.
- 88.* Vloka ME, Babaev A, Ehlert FA, Narula DD, **Steinberg JS**. Poor correlation of automated and manual QT dispersion measurements in patients and normal subjects. *J Am Coll Cardiol* 1999;33:350A.
- 89.* Kaddaha R, Narula DD, Fefer F, Ehlert FA, **Steinberg JS**. Atrial defibrillation using the conventional implantable cardioverter defibrillator. *J Am Coll Cardiol* 1999;33:146A.
- 90.* **Steinberg JS**, Tullo NG, Anderson JL, Beckman K, Crevey BJ, Friedman PL, Green HL, Larsen GC, Rizo-Patron C, Russo AM, Zipes DP, Moore RT, Hallstrom AP and the AVID Investigators. Relationship of coronary perfusion and stenosis to arrhythmic events in the antiarrhythmics versus implantable defibrillators. *J Am Coll Cardiol* 1999;33:119A.
- 91.* Sutandar A, Tamis JE, Narula D, Gemayel CY, Vloka ME, **Steinberg JS**. Atrial fibrillation after minimally invasive bypass surgery is not less frequent than after CABG. *PACE* 1999;22:719.
- 92.* Vloka ME, Sutandar A, Kaddaha RM, Babaev A, Narula DD, **Steinberg JS**. Is there any value to routine pre-ICD electrophysiologic study for patients with ventricular tachyarrhythmias? *Circulation* 1999;100:I-571.
- 93.* **Steinberg JS**, Vloka ME, Yao Q, Schron E, Dorian P, Powell J, AVID Investigators. Relationship of baseline quality of life scores to long-term survival in the antiarrhythmics versus implantable defibrillators (AVID) trial. *Circulation* 1999;100:I-367.

ABSTRACTS (cont'd)

- 94.* **Steinberg JS**, Morris M, Beckman K, Klein RC, and the AVID Syncope Substudy Investigators. Outcome of patients with unexplained syncope, structural heart disease and inducible ventricular tachycardia: final results of the AVID substudy. *Circulation* 1999;100:I-366.
- 95.* Sutandar A, Solimon S, Kaddaha R, Vloka ME, **Steinberg JS**. Should all patients receive a dual chamber device? Unanticipated use of the implantable defibrillator as a pacemaker. *J Am Coll Cardiol* 2000;35:127A.
- 96.* Narula DD, Jaber WA, Vloka ME, Kim JS, Larsen MD, Kaddaha RM, Ehlert FE, **Steinberg JS**. Variations in selection of dual chamber and rate responsive pacemakers: influence of geographic region and physician gender. *J Am Coll Cardiol* 2000;35:141A.
97. Narula DD, Jaber WA, Vloka ME, Kim JS, Larsen MD, Sutandar A, Ehlert FA, **Steinberg JS**. Adjusted pacemaker implant rates are lower in women than men at all ages – is gender bias at work? *J Am Coll Cardiol* 2000;35:142A.
98. Exner D, Schron EB, Yao Q, Vloka ME, Page RL, Powell J, **Steinberg JS**. Defibrillator shocks and self-perceived quality of life in the antiarrhythmics versus implantable defibrillators (AVID) trial. *J Am Coll Cardiol* 2000;35:153A.
- 99.* **Steinberg JS**, Paquette M, Dorian P, Newman D, Vloka M, Schron E, Jenkins L, McBurnie M. Detailed analysis of quality of life responses by patients in AVID: relationship to mortality. *PACE* 2000; 23:568.
- 100.* Tamis JE, Narula DD, Verma PB, Ehlert FA, Menshavez E, **Steinberg JS**. Are IV beta-blockers superior to oral beta-blockers in preventing atrial fibrillation after coronary artery bypass surgery: results of a randomized pilot study. *ANE* 2000; 5:S17.
- 101.* Herweg B, Rill V, Kaddaha RM, Cohen AJ, **Steinberg JS**. Atrial flutter is associated with activation of the endogenous coagulation system. *Circulation* 2000; I-102.
- 102.* Herweg B, Matin ZM, Kaddaha RM, Ehlert FA, Vloka ME, Cohen AJ, **Steinberg JS**. Elevated levels of Factor VIII: C in patients with atrial flutter and decreased left ventricular function. *J Am Coll Cardiol* 2001; 37: 105A.
- 103.* Vloka ME, **Steinberg JS**, Mendelson D, Wharton JM. Predictors of successful cardioversion of atrial fibrillation with a balloon-tipped internal cardioversion catheter. *J Am Coll Cardio* 2001; 37: 130A.
- 104.* **Steinberg JS**, Cohen AJ, for the AFFIRM Investigators. Prethrombotic states in patients with atrial fibrillation followed in AFFIRM. *PACE* 2001; 24:II-640.
- 105.* **Steinberg JS**, Zareba W, Higgin S, Williber D, Daubert J, Moss AJ. Inducibility of ventricular tachyarrhythmias in postinfarction patients with ejection fraction 30%: experience from MADIT II. *PACE* 2001; 24: II-555.
106. Cook J, **Steinberg JS**, Vidaillet H, Zimmerman P, Epstein A, Dalquist J, and the AFFIRM Investigators. Gender differences in the characteristics and prior treatment of Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. *Circulation* 2001; 104: II-699.

ABSTRACTS (cont'd)

- 107.* Herweg B, Chaudhry F, Singh B, Cohen AJ, **Steinberg JS**. Spontaneous echo contrast and decreased left atrial appendage emptying velocity in patients with isthmus-dependent atrial flutter are associated with increased activity of thrombin-antithrombin III complex and prothrombin fragments. *Circulation* 2001; 104: II-716
108. Wojciech Z, Moss, AJ, Gudavali A, **Steinberg JS** . Inverse association between NYHA class and inducibility of sustained ventricular tachycardia or ventricular fibrillation in postinfarction patients with low ejection fraction. *Circulation* 2001; 104: II-784.
- 109.* Babaev A, Suma V, Tita C, **Steinberg JS**. High recurrence rate of atrial flutter after initial presentation in patients on drug treatment: case for ablation as first line therapy. *J Am Coll Cardiol* 2002;39: 83A.
- 110.* Polosajian L, Herweg B, Sichrovsky T, Hefer D, Rozenshtein A, **Steinberg JS**. Pulmonary vein diameter is increased in patients with paroxysmal atrial fibrillation compared to aged-matched controls. *J Am Coll Cardiol* 2002; 39: 116A.
- 111.* Arshad A, Kowalski M, Arshad R, Khilnani R, **Steinberg JS**, Sackner-Bernstein J. Ventricular conduction identifies early hazard after heart failure hospitalization: An earlier role for biventricular pacing? *PACE* 2002; 24: 623.
112. * **Steinberg JS**, Arshad A, Kowalski M, Kukar A, Suma V, Homel P, Rozanski A. The World Trade Center attack: effect on the occurrence of life-threatening ventricular arrhythmias. *PACE* 2002; 24: 259.
- 113.* Maleki K, Hefer D, Petre L, Mohammadi R, **Steinberg JS**. ICD Therapy: Outcomes. Phantom shocks: incidence and risk factors. *Circulation* 2002; 106:II-407.
114. * Herweg B, Sichrovsky T, Polosajian L, Maleki K, Hefer D, **Steinberg JS**. High prevalence of a common pulmonary vein orifice: implication on ablation technique. *Circulation* 2002; 106:II-500.
115. * Kowalski M, **Steinberg JS**, Arshad A, Kukar A, Suma V, Vloka M, Ehlert F, Herweg B, Donnelly J, Philip J, Rozanski A. A new pattern of cardiac events emerges following the World Trade Center attack. *Circulation* 2002; 106:II-755.
- 116.* Arshad A, Kowalski M, Kukar A, Suma V, Vloka ME, Ehlert FA, Herweg B, Donnelly JE, Philip J, Reed G, Rozanski A, **Steinberg JS**. Frequency of implantable cardioverter defibrillator discharges in New York following the World Trade Center attack. *J Am Coll Cardiol* 2003; 41:86A.
117. * DeRose JJ, Ashton Jr., RC, Belsley S, Shaw R, S wistel DG, Sackner-Bernstein J, **Steinberg JS**. Robotically-assisted ventricular resynchronization therapy following failed coronary sinus cannulation. *J Am Coll Cardiol* 2003; 41-137A.
118. Machado C, Gering L, Bailey W, **Steinberg JS**, Skodaced K, De Metz K. Incidence of delayed conversion in response to atrial therapy in a multicenter atrial conversion therapy ICD trial. *Progress in Biomedical Research*; 8: 15-18.

ABSTRACTS (cont'd)

119. Zareba W, Moss AJ, **Steinberg JS**, Hall WJ, Carroll ER, Andrews ML. Signal-averaged ECG and outcome in MADIT II patients. *PACE* 2003; 26: 943.
- 120.* Arshad A, Sichrovsky TC, Polosajian L, Fayngersh V, Kowalski M, **Steinberg JS**. Signal averaged p-wave duration predicts atrial fibrillation recurrence following pulmonary vein isolation. *PACE* 2003; 26: 953.
121. Daubert JP, Wojciech Z, Schuger CD, Corsello AM, **Steinberg JS**, Leon AR, Moss AJ. Does EPS inducibility in MADIT II patients predict subsequent VT and/or VF events? *PACE* 2003; 26: 960.
- 122.* **Steinberg JS**, Sadaniantz A, Miller JM, Campbell WB, Daubert J, Denny DM, Havranek E, Krahn AD, Kron J, Murray K, Olshansky B, O'Neill G, Sami M, Schmidt S, Storm R, Zabalgoitia M, Nasco E, Greene HL, and the AFFIRM investigators. Comparison of modes of death between randomized treatment strategies in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. *PACE* 2003; 26: 974.
123. Friedman PL, Dubuc M, Green M, Jackman W, Keane D, Marinchak RA, Nazair J, Packer DL, Skanes A, **Steinberg JS**, Stevenson WG, Tchou P, Wilber DJ, Worley SJ. Cryomapping and cryoablation of A-V nodal reentrant supraventricular tachycardia: results from the "Frosty" trial. *PACE* 2003; 26: 979.
- 124.* Maleki K, Mohammadi R, **Steinberg JS**. Thrombus on transseptal sheath: detection by continuous intracardiac ultrasound and successful treatment by aspiration. *PACE* 2003; 26: 987.
- 125.* **Steinberg JS**, Machado C, Gering L, Bailey W, Mitchell K. Use of an implantable defibrillator for detection and treatment of atrial and ventricular tachyarrhythmias: report of the TACHOS Atrial Conversion Therapy (TACT) study. *PACE* 2003; 26: 1019.
- 126.* Hart DT, Petre L, Arshad R, King M, Herweg B, **Steinberg JS**. Assessment of ventricular capture in patients with cardiac resynchronization devices: a simple surface electrocardiographic algorithm. *PACE* 2003; 26: 1083.
127. Perkiomaki JS, Zareba W, **Steinberg JS**, Andrews ML, Carroll ER, Moss AJ. Relationship of heart rate variability and signal-averaged electrocardiographic parameters to inducibility of ventricular tachyarrhythmias in postinfarction patients with reduced left ventricular function. *PACE* 2003; 26: 1091.
- 128.* **Steinberg JS**, Maniar P, Zareba W, Wang P, Schuger C, Daubert J, Andrews M, Brown M, Moss AJ for the MADIT-II Investigators. The relationship of right ventricular pacing and outcome in the MADIT-II patients. Presented at NASPE 2003 as Late Breaking Clinical Trial.
129. Weiford BC, Vacek JL, Emert MP, Zareba W, Andrews ML, Carroll E, Jackson Hall W, Brown MW, **Steinberg JS**, Moss AJ, Berenbom LD. Effect of single- versus dual-chamber ICDs on heart failure and mortality in the MADIT-II study. *Circulation* 2003; 108:IV 364.
130. Sharma AD, Rizo-Patron C, Hallstrom A, O'Neill G, Rothbart S, Martins J, Roelke M, **Steinberg J**, Greene L, DAVID investigators. Right ventricular pacing percent independently predicts outcomes in the DAVID trial. *Circulation* 2003; 108:IV 628.

ABSTRACTS (cont'd)

131. Carson P, Anand I, O'Connor CM, Lindenfeld J, **Steinberg J**, Ghali J, Jaski B, Lwin A, Feldman A, Bristow M. Relation of cardiac device therapy to mode of death in advanced heart failure – COMPANION Trial. *Circulation* 2003; 108:IV 628.
- 132*. Hart D, Sichrovsky T, Cotiga D, Farhat N, Maleki K, Vloka ME, **Steinberg JS**. Prevention of thrombus formation on left atrial sheaths with high-dose heparinized saline flush: results of a prospective study. *Circulation* 2003; 108:IV 423.
133. Balaram SK, Ashton RC, **Steinberg JS**, Swistel DG, Ehlert F, Vloka ME, and DeRose, JJ. Success of robotic bi-ventricular pacing following open heart surgery: the importance of the posterior approach. *Heart Surgery* (in press).
134. Balaram SK, Ashton RC, **Steinberg JS**, Swistel DG, Ehlert F, Vloka ME, and DeRose JJ. Left ventricular epicardial lead stability following robotically-assisted ventricular resynchronization. *Heart Surgery* (in press).
135. * Herweg B, Sichrovsky TC, Petrel L, Polosajian L, **Steinberg JS**, Relationship of ostial pulmonary vein diameter to hypertension and left ventricular hypertrophy in patients with atrial fibrillation. *J Am Coll Cardiol* 2004;43:118A.
136. Shedd OL, **Steinberg JS**, Arshad A, Harvill J, Curtis A, The World Trade Center attack: increased frequency of defibrillator shocks for ventricular arrhythmias in patients living remotely from New York City. *J Am Coll Cardiol* 2004;43:125A.
137. Balaram KB, Ashton RC, Jr, **Steinberg JS**, Swistel DG, Ehlert FE, Vloka MV, DeRose JD, Jr. Improved response rate and left ventricular epicardial lead stability following robotically-assisted ventricular resynchronization. *J Am Coll Cardiol* 2004;43:146A
138. Balaram SK, Ashton RC, **Steinberg JS**, Swistel DG, Ehlert F, Vloka ME, and DeRose JJ. Left-ventricular mapping results in improved response rates for robotically-assisted bi-ventricular pacing. *ISMICS 2004 (Heart Surgery Forum)*;7:Suppl 1, S20.
139. Vyas AK, Moss AJ, Olshansky B, Guo H, **Steinberg JS**, Fischer A, Jackson Hall W., McNitt S, and Andrews ML. Lipid-lowering agents reduce ventricular tacharrhythmias in MADIT-II. *Heart Rhythm* 2004;1:S264.
140. * Arshad A, Cotiga D, Musat D, Chaudhry F, **Steinberg JS**, Diagnosis of diastolic dysfunction using intracardiac ultrasound of pulmonary vein flow in patients undergoing ablation: Relationship to success of procedure. *Circulation* 2004;110: III-350.
- 141.* Arshad A, Cotiga D, Khan A, Kasaryan H, Joshi S, **Steinberg JS**. Mechanical provocation of atrial fibrillation in the pulmonary veins identifies procedure responders after ablation. *Circulation* 2004;110: III-418.
- 142.* Balaram SK, Ashton RC, **Steinberg JS**, Swistel DG, Ehlert F, Vloka ME, and DeRose, JJ. "Success of Robotic Bi-Ventricular Pacing Following Open Heart Surgery: The Importance of the Posterior Approach." *Cardiothoracic Techniques and Technologies* 2004;108, page 159.

ABSTRACTS (cont'd)

143. Carson P, O'Connor C, Lindenfeld J, Ghali J, Jaski B, **Steinberg JS**, Barnet J, Anand I, Dept. of Veterans Affairs Medical Center. Total hospitalizations in advanced heart failure: Results from COMPANION J Am Coll Cardiol.;45: 145A.
- 144.* Sichrovsky TC, Arshad A, Joshi S, Kamra A, Weathers L, **Steinberg JS**. Pulmonary vein isolation yields high success rates in persistent atrial fibrillation. J Am Coll Cardiol;45: 124A.
- 145.* Joshi S, Gowda SA, DeRose JJ, Ashton RC, Vloka MC, Kukin MC, Chaudhry FA, Fischer A, Pierce W, Ehlert FC, **Steinberg JS**. Reverse remodeling with robotic surgical resynchronization. Hearh Rhythm 2005;2:P3-85.
- 146.* Cotiga D, Arshad A, Joshi S, Fischer A, **Steinberg JS**. Unusually high acute pharmacologic conversion rate during dofetilide initiation. Hearh Rhythm 2005;2:P4-50.
147. Lindenfeld J, Feldman A, Saxon L, Boehmer J, Carson P, Ghali J, **Steinberg JS**, DeMarco T, Mann D, Yong P, Galle E, Ecklund F, Bristow M. Cardiac resynchronization therapy with and without defibrillator improve time to death and hospitalization in NYHA Class IV heart failure patients. Circulation 2005;112:II-673.
- 148.* Fischer A, Shah A, Pierce W, Ehlert F, Vloka M, **Steinberg JS**. Inappropriate shocks due to T-wave oversensing in St. Jude Medical implantable defibrillators: Importance of sensing algorithm and programmed values. Circulation 2005;112:II-439.
149. Bangalore S, Kamalakkannan G, **Steinberg JS**, Messerli F. ACE inhibitor associated cough: How reliable is the information from the physicians desk reference (PDR)? Circulation 2005;112:II-609.
- 150.* Shah AS, Sarji R, Pudpud D, Macmillan-Marotti D, Bangalore S, Haridas A, Onuora A, Balaram S, DeRose JJ, **Steinberg JS**, Chaudhry F. Robotic epicardial cardiac resynchronization is superior to endovascular implantation in promoting reverse remodeling. JACC 2006; 810-8:12A.
- 151.* Joshi S, DeRose Jr. JJ, Gopinath DS, Shah A, **Steinberg JS**. Comparison of reverse ventricular remodeling between surgical direct epicardial and transvenous coronary sinus lead placement for cardiac resynchronization therapy. JACC 2006; 1015-125:32A.
- 152.* Saxon LA, **Steinberg JS**, Young P, Galle E, Ecklund F, Bristow MR, COMPANION Study Investigators. Factors associated with unsuccessful coronary venous lead placement and long-term outcome in patients in the COMPANION trial. Heart Rhythm 2006; S101:AB48-6.